

# The Medical Letter®

## On Drugs and Therapeutics

Published by The Medical Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication

Volume 49 (Issue 1275)  
December 3, 2007

www.medicalletter.org

### IN BRIEF

#### Dexrazoxane for Anthracycline Extravasation

The FDA has approved a new formulation of dexrazoxane (*Totect*) for treatment of extravasation from intravenous (IV) anthracyclines such as doxorubicin (*Adriamycin*, and others). Dexrazoxane has been available since 1995 as *Zinecard* for protection against the cardiac toxicity of anthracyclines ([Med Lett Drugs Ther 1995; 37:110](#)). It is also available generically. The drug's precise mechanism of action is not known, but anthracyclines are vesicants that bind to DNA and act as oxidizing agents in the presence of iron. Dexrazoxane is a topoisomerase inhibitor, possibly interfering with anthracycline effects on DNA, and is also a potent iron-chelating agent, preventing free-radical formation. In uncontrolled clinical trials, dexrazoxane appears to have prevented severe necrosis that would require surgical debridement ([HT Mouridsen et al. Ann Oncol 2007; 18:546. epub](#)). It is given in a dose of 1000 mg/m<sup>2</sup> (2000 mg maximum) as an IV infusion over 1-2 hours as soon as possible (no later than 6 hours) after extravasation has occurred and again 24 hours later, and then in a dose of 500 mg/m<sup>2</sup> (1000 mg maximum) 48 hours after the first dose. The dose should be reduced by half in patients with a creatinine clearance <40 mL/min.

### The Medical Letter®

On Drugs and Therapeutics

**EDITOR:** Mark Abramowicz, M.D.  
**DEPUTY EDITOR:** Gianna Zuccotti, M.D., M.P.H., Weill Medical College of Cornell University  
**EDITOR, DRUG INFORMATION:** Jean-Marie Pflomm, Pharm.D.  
**CONTRIBUTING EDITOR, DRUG INTERACTIONS:** Philip D. Hansten, Pharm.D., University of Washington  
**ADVISORY BOARD:**  
Jules Hirsch, M.D., Rockefeller University  
David N. Juurlink, BPhm, M.D., PhD, Sunnybrook Health Sciences Centre  
James D. Kenney, M.D., Yale University School of Medicine  
Richard B. Kim, M.D., University of Western Ontario  
Gerald L. Mandell, M.D., University of Virginia School of Medicine  
Hans Meinertz, M.D., University Hospital, Copenhagen  
Dan M. Roden, M.D., Vanderbilt University School of Medicine  
F. Estelle R. Simons, M.D., University of Manitoba  
Neal H. Steigbigel, M.D., New York University School of Medicine  
**EDITORIAL FELLOWS:**  
Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School  
Lauren K. Schwartz, M.D., Mount Sinai School of Medicine  
**DRUG INTERACTIONS FELLOW:** Emily Ung, BScPhm, Children's Hospital of Western Ontario  
**SENIOR ASSOCIATE EDITORS:** Donna Goodstein, Amy Faucard  
**ASSISTANT EDITOR:** Cynthia Macapagal Covey  
**MANAGING EDITOR:** Susie Wong  
**PRODUCTION COORDINATOR:** Cheryl Brown  
**VP FINANCE & OPERATIONS:** Yosef Wissner-Levy  
Founded in 1959 by  
Arthur Kallet and Harold Aaron, M.D.

**Copyright and Disclaimer:** The Medical Letter is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter is supported solely by subscription fees and accepts no advertising, grants or donations. The content of The Medical Letter is controlled by the Editor, who declares no conflict. The members of the Advisory Board are required to disclose any potential conflict of interest.

No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy or omission.

#### Subscription Services

|  |  |
|--|--|
| <b>Mailing Address:</b><br>The Medical Letter, Inc.<br>1000 Main Street<br>New Rochelle, NY 10801-7537   | <b>Subscriptions (US):</b><br>1 year - \$89; 2 years - \$151;<br>3 years - \$214. \$44.50 per year for students, interns, residents and fellows in the US and Canada.<br>CME: \$44 for 26 credits.                                   |
| <b>Customer Service:</b><br>Call: 800-211-2769 or 914-235-0500<br>Fax: 914-632-1733<br>Web Site: www.medicalletter.org<br>E-mail: custserv@medicalletter.org | <b>E-mail site license inquiries to:</b><br>info@medicalletter.org or call 800-211-2769 x315.<br>Special fees for bulk subscriptions. Special classroom rates are available. Back issues are \$12 each. Major credit cards accepted. |
| <b>Permissions:</b><br>To reproduce any portion of this issue, please e-mail your request to: permissions@medicalletter.org                                  |  |

Copyright 2007. ISSN 1523-2859